|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giuliani ME, Lindsay PE, Kwan JY, Sun A,
Bezjak A, Le LW, Brade A, Cho J, Leighl NB, Shepherd FA and Hope
AJ: Correlation of dosimetric and clinical factors with the
development of esophagitis and radiation pneumonitis in patients
with limited-stage small-cell lung carcinoma. Clin Lung Cancer.
16:216–220. 2015. View Article : Google Scholar
|
|
3
|
Han S, Gu F, Lin G, Sun X, Wang Y, Wang Z,
Lin Q, Weng D, Xu Y and Mao W: Analysis of clinical and dosimetric
factors influencing radiation-induced lung injury in patients with
lung cancer. J Cancer. 6:1172–1178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Briere TM, Krafft S, Liao Z and Martel MK:
Lung size and the risk of radiation pneumonitis. Int J Radiat Oncol
Biol Phys. 94:377–384. 2016. View Article : Google Scholar
|
|
5
|
Podralska M, Ciesielska S, Kluiver J, van
den Berg A, Dzikiewicz-Krawczyk A and Slezak-Prochazka I:
Non-coding RNAs in cancer radiosensitivity: MicroRNAs and lncRNAs
as regulators of radiation-induced signaling pathways. Cancers
(Basel). 12:16622020. View Article : Google Scholar
|
|
6
|
Dreussi E, Pucciarelli S, De Paoli A,
Polesel J, Canzonieri V, Agostini M, Friso ML, Belluco C,
Buonadonna A, Lonardi S, et al: Predictive role of microRNA-related
genetic polymorphisms in the pathological complete response to
neoadjuvant chemoradiotherapy in locally advanced rectal cancer
patients. Oncotarget. 7:19781–19793. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fanale D, Castiglia M, Bazan V and Russo
A: Involvement of non-coding RNAs in chemo- and radioresistance of
colorectal cancer. Adv Exp Med Biol. 937:207–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan S, Xia L, Yi P, Han Y, Tang L, Pan Q,
Tian Y, Rao S, Oyang L, Liang J, et al: Exosomal miRNAs in tumor
microenvironment. J Exp Clin Cancer Res. 39:672020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patil N, Allgayer H and Leupold JH:
MicroRNAs in the tumor microenvironment. Adv Exp Med Biol.
1277:1–31. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: A new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Movahedpour A, Ahmadi N, Ghasemi Y,
Savardashtaki A and Shabaninejad Z: Circulating microRNAs as
potential diagnostic biomarkers and therapeutic targets in prostate
cancer: Current status and future perspectives. J Cell Biochem.
120:16316–16329. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sohel MH: Extracellular/circulating
MicroRNAs: Release mechanisms, functions and challenges. Achiev
Life Sci. 10:175–186. 2016.
|
|
15
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fernandes JCR, Acuña SM, Aoki JI,
Floeter-Winter LM and Muxel SM: Long non-coding RNAs in the
regulation of gene expression: Physiology and disease. Noncoding
RNA. 5:172019.
|
|
17
|
Statello L, Guo CJ, Chen LL and Huarte M:
Gene regulation by long non-coding RNAs and its biological
functions. Nat Rev Mol Cell Biol. Dec 22–2020.Epub ahead of print.
PubMed/NCBI
|
|
18
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu K, Gao L, Ma X, Huang JJ, Chen J, Zeng
L, Ashby CR Jr, Zou C and Chen ZS: Long non-coding RNAs regulate
drug resistance in cancer. Mol Cancer. 19:542020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu Y, Zhao Y, Dong S, Liu L, Tai L and Xu
Y: Systematic identification of dysregulated lncRNAs associated
with platinum-based chemotherapy response across 11 cancer types.
Genomics. 112:1214–1222. 2020. View Article : Google Scholar
|
|
22
|
Huang L, Zeng L, Chu J, Xu P, Lv M, Xu J,
Wen J, Li W, Wang L, Wu X, et al: Chemoresistance-related long
non-coding RNA expression profiles in human breast cancer cells.
Mol Med Rep. 18:243–253. 2018.PubMed/NCBI
|
|
23
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
24
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lo AC, Soliman AS, Khaled HM, Aboelyazid A
and Greenson JK: Lifestyle, occupational, and reproductive factors
and risk of colorectal cancer. Dis Colon Rectum. 53:830–837. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Basen-Engquist K and Chang M: Obesity and
cancer risk: Recent review and evidence. Curr Oncol Rep. 13:71–76.
2011. View Article : Google Scholar
|
|
28
|
De Roos AJ, Ray RM, Gao DL, Fitzgibbons
ED, Ziding F, Astrakianakis G, Thomas DB and Checkoway H:
Colorectal cancer incidence among female textile workers in
Shanghai, China: A case-cohort analysis of occupational exposures.
Cancer Causes Control. 16:1177–1188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oddone E, Modonesi C and Gatta G:
Occupational exposures and colorectal cancers: A quantitative
overview of epidemiological evidence. World J Gastroenterol.
20:12431–12444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rattray NJW, Charkoftaki G, Rattray Z,
Hansen JE, Vasiliou V and Johnson CH: Environmental influences in
the etiology of colorectal cancer: The premise of metabolomics.
Curr Pharmacol Rep. 3:114–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peters RK, Garabrant DH, Yu MC and Mack
TM: A case-control study of occupational and dietary factors in
colorectal cancer in young men by subsite. Cancer Res.
49:5459–5468. 1989.PubMed/NCBI
|
|
32
|
Wang Y, Lewis-Michl EL, Hwang SA,
Fitzgerald EF and Stark AD: Cancer incidence among a cohort of
female farm residents in New York State. Arch Environ Health.
57:561–567. 2002. View Article : Google Scholar
|
|
33
|
Wesseling C, Antich D, Hogstedt C,
Rodríguez AC and Ahlbom A: Geographical differences of cancer
incidence in Costa Rica in relation to environmental and
occupational pesticide exposure. Int J Epidemiol. 28:365–374. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rushton L, Hutchings S and Brown T: The
burden of cancer at work: Estimation as the first step to
prevention. Occup Environ Med. 65:789–800. 2008. View Article : Google Scholar
|
|
35
|
Toiyama Y and Kusunoki M: Changes in
surgical therapies for rectal cancer over the past 100 years: A
review. Ann Gastroenterol Surg. 4:331–342. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Knol J and Keller DS: Total mesorectal
excision technique-past, present, and future. Clin Colon Rectal
Surg. 33:134–143. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kapiteijn E, Marijnen CA, Nagtegaal ID,
Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B,
van Krieken JH, et al: Preoperative radiotherapy combined with
total mesorectal excision for resectable rectal cancer. N Engl J
Med. 345:638–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roeder F, Meldolesi E, Gerum S, Valentini
V and Rödel C: Recent advances in (chemo-)radiation therapy for
rectal cancer: A comprehensive review. Radiat Oncol. 15:2622020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Heald RJ, Husband EM and Ryall RD: The
mesorectum in rectal cancer surgery-the clue to pelvic recurrence?
Br J Surg. 69:613–616. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hermanek P, Hermanek P, Hohenberger W,
Klimpfinger M, Köckerling F and Papadopoulos T: The pathological
assessment of mesorectal excision: Implications for further
treatment and quality management. Int J Colorectal Dis. 18:335–341.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
MacFarlane JK, Ryall RD and Heald RJ:
Mesorectal excision for rectal cancer. Lancet. 341:457–460. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Havenga K, Enker WE, Norstein J, Moriya Y,
Heald RJ, van Houwelingen HC and van de Velde CJ: Improved survival
and local control after total mesorectal excision or D3
lymph-adenectomy in the treatment of primary rectal cancer: An
international analysis of 1411 patients. Eur J Surg Oncol.
25:368–374. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Randomised trial of surgery alone versus
radiotherapy followed by surgery for potentially operable locally
advanced rectal cancer. Medical research council rectal cancer
working party Lancet. 348:1605–1610. 1996.
|
|
45
|
Kim SH, Lee JM, Hong SH, Kim GH, Lee JY,
Han JK and Choi BI: Locally advanced rectal cancer: Added value of
diffusion-weighted MR imaging in the evaluation of tumor response
to neoadjuvant chemo- and radiation therapy. Radiology.
253:116–125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Christou N, Meyer J, Toso C, Ris F and
Buchs NC: Lateral lymph node dissection for low rectal cancer: Is
it necessary? World J Gastroenterol. 25:4294–4299. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Benson AB, Venook AP, Al-Hawary MM, Arain
MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Garrido-Laguna I, et al: NCCN Guidelines insights: Rectal cancer,
version 6.2020. J Natl Compr Canc Netw. 18:806–815. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang S, Bai W, Tong X, Bu P, Xu J and Xi
Y: Correlation between tumor microenvironment-associated factors
and the efficacy and prognosis of neoadjuvant therapy for rectal
cancer. Oncol Lett. 17:1062–1070. 2019.PubMed/NCBI
|
|
49
|
Ma B, Gao P, Song Y, Huang X, Wang H, Xu
Q, Zhao S and Wang Z: Short-course radiotherapy in neoadjuvant
treatment for rectal cancer: A systematic review and meta-analysis.
Clin Colorectal Cancer. 17:320–330.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bujko K, Wyrwicz L, Rutkowski A,
Malinowska M, Pietrzak L, Kryński J, Michalski W, Olędzki J,
Kuśnierz J, Zając L, et al: Long-course oxaliplatin-based
preoperative chemoradiation versus 5×5 Gy and consolidation
chemotherapy for cT4 or fixed cT3 rectal cancer: Results of a
randomized phase III study. Ann Oncol. 27:834–842. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
From the American Association of
Neurological Surgeons (AANS); American Society of Neuroradiology
(ASNR); Canadian Interventional Radiology Association (CIRA);
Congress of Neurological Surgeons (CNS); European Society of
Minimally Invasive Neurological Therapy (ESMINT); European Society
of Neuroradiology (ESNR); European Stroke Organization (ESO);
Society for Cardiovascular Angiography; Interventions (SCAI);
Society of Interventional Radiology (SIR); Society of
Interventional Radiology (SIR); et al: Multisociety consensus
quality improvement revised consensus statement for endovascular
therapy of acute ischemic stroke. Int J Stroke. 13:612–632.
2018.PubMed/NCBI
|
|
52
|
Ngan SY, Burmeister B, Fisher RJ, Solomon
M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B,
McLachlan SA, et al: Randomized trial of short-course radiotherapy
versus long-course chemoradiation comparing rates of local
recurrence in patients with T3 rectal cancer: Trans-Tasman
radiation oncology group trial 01.04. J Clin Oncol. 30:3827–3833.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
McLachlan SA, Fisher RJ, Zalcberg J,
Solomon M, Burmeister B, Goldstein D, Leong T, Ackland SP,
McKendrick J, McClure B, et al: The impact on health-related
quality of life in the first 12 months: A randomised comparison of
preoperative short-course radiation versus long-course
chemoradiation for T3 rectal cancer (Trans-Tasman Radiation
Oncology Group Trial 01.04). Eur J Cancer. 55:15–26. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mowery YM, Salama JK, Zafar SY, Moore HG,
Willett CG, Czito BG, Hopkins MB and Palta M: Neoadjuvant
long-course chemoradiation remains strongly favored over
short-course radiotherapy by radiation oncologists in the United
States. Cancer. 123:1434–1441. 2017. View Article : Google Scholar
|
|
55
|
Glynne-Jones R, Wyrwicz L, Tiret E, Brown
G, Rödel C, Cervantes A and Arnold D; ESMO Guidelines Committee:
Rectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 29(Suppl 4): iv2632018.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sineshaw HM, Jemal A, Thomas CR Jr and
Mitin T: Changes in treatment patterns for patients with locally
advanced rectal cancer in the United States over the past decade:
An analysis from the national cancer data base. Cancer.
122:1996–2003. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang X, Zheng B, Lu X, Bai R, Feng L, Wang
Q, Zhao Y and He S: Preoperative short-course radiotherapy and
long-course radiochemotherapy for locally advanced rectal cancer:
Meta-analysis with trial sequential analysis of long-term survival
data. PLoS One. 13:e02001422018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Otero de Pablos J and Mayol J:
Controversies in the management of lateral pelvic lymph nodes in
patients with advanced rectal cancer: East or west? Front Surg.
6:792019. View Article : Google Scholar
|
|
59
|
Watanabe T, Muro K, Ajioka Y, Hashiguchi
Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S,
et al: Japanese society for cancer of the colon and rectum (JSCCR)
guidelines 2016 for the treatment of colorectal cancer. Int J Clin
Oncol. 23:1–34. 2018. View Article : Google Scholar :
|
|
60
|
Tokuhara K, Ueyama Y, Nakatani K, Yoshioka
K and Kon M: Outcomes of neoadjuvant chemoradiotherapy in Japanese
locally advanced rectal carcinoma patients. World J Surg Oncol.
14:1362016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Numasaki H, Shibuya H, Nishio M, Ikeda H,
Sekiguchi K, Kamikonya N, Koizumi M, Tago M, Ando Y, Tsukamoto N,
et al: Japanese structure survey of radiation oncology in 2007 with
special reference to designated cancer care hospitals. Strahlenther
Onkol. 187:167–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Teshima T, Numasaki H, Shibuya H, Nishio
M, Ikeda H, Sekiguchi K, Kamikonya N, Koizumi M, Tago M, Ando Y, et
al: Japanese structure survey of radiation oncology in 2007 based
on institutional stratification of patterns of care study. Int J
Radiat Oncol Biol Phys. 78:1483–1493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Minsky BD, Cohen AM, Enker WE, Sigurdson E
and Harrison LB: Radiation therapy for unresectable rectal cancer.
Int J Radiat Oncol Biol Phys. 21:1283–1289. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang G, Wang W, Jin H, Dong H, Chen W, Li
X, Li G and Li L: The effect of primary tumor radiotherapy in
patients with unresectable stage IV rectal or rectosigmoid cancer:
A propensity score matching analysis for survival. Radiat Oncol.
15:1262020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
van der Valk MJM, Hilling DE, Bastiaannet
E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama
A, Perez RO, Renehan AG and van de Velde CJH: IWWD Consortium:
Long-term outcomes of clinical complete responders after
neoadjuvant treatment for rectal cancer in the international watch
& wait database (IWWD): An international multicentre registry
study. Lancet. 391:2537–2545. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhao F, Wang J, Yu H, Cheng X, Li X, Zhu
X, Xu X, Lin J, Chen X and Yan S: Neoadjuvant radiotherapy improves
overall survival for T3/4N+M0 rectal cancer patients: A
population-based study of 20300 patients. Radiat Oncol. 15:492020.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Petrelli F, Trevisan F, Cabiddu M, Sgroi
G, Bruschieri L, Rausa E, Ghidini M and Turati L: Total neoadjuvant
therapy in rectal cancer: A systematic review and meta-analysis of
treatment outcomes. Ann Surg. 271:440–448. 2020. View Article : Google Scholar
|
|
68
|
Cercek A, Roxburgh CSD, Strombom P, Smith
JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK,
et al: Adoption of total neoadjuvant therapy for locally advanced
rectal cancer. JAMA Oncol. 4:e1800712018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gilshtein H, Ghuman A, Dawoud M, Yellinek
S, Kent I, Sharp SP, Nagarajan A and Wexner SD: Total neoadjuvant
treatment for rectal cancer: Preliminary experience. Am Surg. Nov
10–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
den Dulk M, Krijnen P, Marijnen CA, Rutten
HJ, van de Poll-Franse LV, Putter H, Meershoek-Klein Kranenbarg E,
Jansen-Landheer ML, Coebergh JW and van de Velde CJ: Improved
overall survival for patients with rectal cancer since 1990: The
effects of TME surgery and pre-operative radio-therapy. Eur J
Cancer. 44:1710–1716. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Birgisson H, Påhlman L, Gunnarsson U and
Glimelius B: Late adverse effects of radiation therapy for rectal
cancer-a systematic overview. Acta Oncol. 46:504–516. 2007.
View Article : Google Scholar
|
|
72
|
Bruheim K, Guren MG, Skovlund E, Hjermstad
MJ, Dahl O, Frykholm G, Carlsen E and Tveit KM: Late side effects
and quality of life after radiotherapy for rectal cancer. Int J
Radiat Oncol Biol Phys. 76:1005–1011. 2010. View Article : Google Scholar
|
|
73
|
Joye I and Haustermans K: Early and late
toxicity of radiotherapy for rectal cancer. Recent Results Cancer
Res. 203:189–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Marijnen CA, Kapiteijn E, van de Velde CJ,
Martijn H, Steup WH, Wiggers T, Kranenbarg EK and Leer JW;
Cooperative Investigators of the Dutch Colorectal Cancer Group:
Acute side effects and complications after short-term preoperative
radio-therapy combined with total mesorectal excision in primary
rectal cancer: Report of a multicenter randomized trial. J Clin
Oncol. 20:817–825. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Frykholm GJ, Isacsson U, Nygård K,
Montelius A, Jung B, Påhlman L and Glimelius B: Preoperative
radiotherapy in rectal carcinoma-aspects of acute adverse effects
and radiation technique. Int J Radiat Oncol Biol Phys.
35:1039–1048. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sipaviciute A, Sileika E, Burneckis A and
Dulskas A: Late gastrointestinal toxicity after radiotherapy for
rectal cancer: A systematic review. Int J Colorectal Dis.
35:977–983. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Swedish Rectal Cancer Trial; Cedermark B,
Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE and Wilking N:
Improved survival with preoperative radiotherapy in resectable
rectal cancer. N Engl J Med. 336:980–987. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
van Gijn W, Marijnen CA, Nagtegaal ID,
Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius
B and van de Velde CJ; Dutch Colorectal Cancer Group: Preoperative
radiotherapy combined with total mesorectal excision for resectable
rectal cancer: 12-year follow-up of the multicentre, randomised
controlled TME trial. Lancet Oncol. 12:575–582. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Randomized study on preoperative
radiotherapy in rectal carcinoma. Stockholm colorectal cancer study
group. Ann Surg Oncol. 3:423–430. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Birgisson H, Påhlman L, Gunnarsson U and
Glimelius B; Swedish Rectal Cancer Trial Group: Adverse effects of
preoperative radiation therapy for rectal cancer: Long-term
follow-up of the Swedish rectal cancer trial. J Clin Oncol.
23:8697–8705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Peeters KC, van de Velde CJ, Leer JW,
Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T,
Rutten HJ and Marijnen CA: Late side effects of short-course
preoperative radiotherapy combined with total mesorectal excision
for rectal cancer: Increased bowel dysfunction in irradiated
patients-a Dutch colorectal cancer group study. J Clin Oncol.
23:6199–6206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pollack J, Holm T, Cedermark B, Altman D,
Holmström B, Glimelius B and Mellgren A: Late adverse effects of
short-course preoperative radiotherapy in rectal cancer. Br J Surg.
93:1519–1525. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Marijnen CA, van de Velde CJ, Putter H,
van den Brink M, Maas CP, Martijn H, Rutten HJ, Wiggers T,
Kranenbarg EK, Leer JW and Stiggelbout AM: Impact of short-term
preoperative radiotherapy on health-related quality of life and
sexual functioning in primary rectal cancer: Report of a
multicenter randomized trial. J Clin Oncol. 23:1847–1858. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Frykholm GJ, Glimelius B and Påhlman L:
Preoperative or postoperative irradiation in adenocarcinoma of the
rectum: Final treatment results of a randomized trial and an
evaluation of late secondary effects. Dis Colon Rectum. 36:564–572.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Shi Y, Liu N, Lai W, Yan B, Chen L, Liu S,
Liu S, Wang X, Xiao D, Liu X, et al: Nuclear EGFR-PKM2 axis induces
cancer stem cell-like characteristics in irradiation-resistant
cells. Cancer Lett. 422:81–93. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Yan B, Liu S, Shi Y, Liu N, Chen L, Wang
X, Xiao D, Liu X, Mao C, Jiang Y, et al: Activation of AhR with
nuclear IKKα regulates cancer stem-like properties in the
occurrence of radio-resistance. Cell Death Dis. 9:4902018.
View Article : Google Scholar
|
|
87
|
Rycaj K and Tang DG: Cancer stem cells and
radioresistance. Int J Radiat Biol. 90:615–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li F, Zhou K, Gao L, Zhang B, Li W, Yan W,
Song X, Yu H, Wang S, Yu N and Jiang Q: Radiation induces the
generation of cancer stem cells: A novel mechanism for cancer
radioresistance. Oncol Lett. 12:3059–3065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hartley A, Ho KF, McConkey C and Geh JI:
Pathological complete response following pre-operative
chemoradiotherapy in rectal cancer: Analysis of phase II/III
trials. Br J Radiol. 78:934–938. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sinukumar S, Patil P, Engineer R, Desouza
A and Saklani A: Clinical outcome of patients with complete
pathological response to neoadjuvant chemoradiotherapy for locally
advanced rectal cancers: The Indian scenario. Gastroenterol Res
Pract. 2014:8678412014. View Article : Google Scholar
|
|
91
|
Valentini V, Aristei C, Glimelius B,
Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P,
Overgaard J, Pahlman L, et al: Multidisciplinary rectal cancer
management: 2nd European rectal cancer consensus conference
(EURECA-CC2). Radiother Oncol. 92:148–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Gérard JP, Conroy T, Bonnetain F, Bouché
O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E,
Maurel J, et al: Preoperative radiotherapy with or without
concurrent fluorouracil and leucovorin in T3-4 rectal cancers:
Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yoon WH, Kim HJ, Kim CH, Joo JK, Kim YJ
and Kim HR: Oncologic impact of pathologic response on clinical
outcome after preoperative chemoradiotherapy in locally advanced
rectal cancer. Ann Surg Treat Res. 88:15–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Pozo ME and Fang SH: Watch and wait
approach to rectal cancer: A review. World J Gastrointest Surg.
7:306–312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Renehan AG, Malcomson L, Emsley R, Gollins
S, Maw A, Myint AS, Rooney PS, Susnerwala S, Blower A, Saunders MP,
et al: Watch-and-wait approach versus surgical resection after
chemoradiotherapy for patients with rectal cancer (the OnCoRe
project): A propensity-score matched cohort analysis. Lancet Oncol.
17:174–183. 2016. View Article : Google Scholar
|
|
96
|
Chan N, Milosevic M and Bristow RG: Tumor
hypoxia, DNA repair and prostate cancer progression: New targets
and new therapies. Future Oncol. 3:329–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Anastasiadou E, Jacob LS and Slack FJ:
Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018.
View Article : Google Scholar
|
|
98
|
Zhu J, Chen S, Yang B, Mao W, Yang X and
Cai J: Molecular mechanisms of lncRNAs in regulating cancer cell
radiosensitivity. Biosci Rep. 39:BSR201905902019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Sole C, Arnaiz E, Manterola L, Otaegui D
and Lawrie CH: The circulating transcriptome as a source of cancer
liquid biopsy biomarkers. Semin Cancer Biol. 58:100–108. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Li N, Yu J, Luo A, Tang Y, Liu W, Wang S,
Liu Y, Song Y, Fang H, Chen B, et al: LncRNA and mRNA signatures
associated with neoadjuvant chemoradiotherapy downstaging effects
in rectal cancer. J Cell Biochem. 120:5207–5217. 2019. View Article : Google Scholar
|
|
101
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta.
1859:169–176. 2016. View Article : Google Scholar
|
|
102
|
Cao MX, Jiang YP, Tang YL and Liang XH:
The crosstalk between lncRNA and microRNA in cancer metastasis:
Orchestrating the epithelial-mesenchymal plasticity. Oncotarget.
8:12472–12483. 2017. View Article : Google Scholar :
|
|
103
|
Ferrando L, Cirmena G, Garuti A, Scabini
S, Grillo F, Mastracci L, Isnaldi E, Marrone C, Gonella R, Murialdo
R, et al: Development of a long non-coding RNA signature for
prediction of response to neoadjuvant chemoradiotherapy in locally
advanced rectal adenocarcinoma. PLoS One. 15:e02265952020.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wang ZK, Yang L, Wu LL, Mao H, Zhou YH,
Zhang PF and Dai GH: Long non-coding RNA LINC00261 sensitizes human
colon cancer cells to cisplatin therapy. Braz J Med Biol Res.
51:e67932017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Liao J and Dong LP: Linc00261 suppresses
growth and metastasis of non-small cell lung cancer via repressing
epithelial-mesenchymal transition. Eur Rev Med Pharmacol Sci.
23:3829–3837. 2019.PubMed/NCBI
|
|
106
|
Fang Q, Sang L and Du S: Long noncoding
RNA LINC00261 regulates endometrial carcinoma progression by
modulating miRNA/FOXO1 expression. Cell Biochem Funct. 36:323–330.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Drebber U, Lay M, Wedemeyer I, Vallböhmer
D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP
and Odenthal M: Altered levels of the onco-microRNA 21 and the
tumor-supressor microRNAs 143 and 145 in advanced rectal cancer
indicate successful neoadjuvant chemoradiotherapy. Int J Oncol.
39:409–415. 2011.PubMed/NCBI
|
|
108
|
Zhu H, Zhu X, Cheng G, Zhou M and Lou W:
Downregulation of microRNA-21 enhances radiosensitivity in
nasopharyngeal carcinoma. Exp Ther Med. 9:2185–2189. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Huang Q: Predictive relevance of ncRNAs in
non-small-cell lung cancer patients with radiotherapy: A review of
the published data. Biomark Med. 12:1149–1159. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Lopes-Ramos CM, Habr-Gama A, Quevedo Bde
S, Felício NM, Bettoni F, Koyama FC, Asprino PF, Galante PA,
Gama-Rodrigues J, Camargo AA, et al: Overexpression of miR-21-5p as
a predictive marker for complete tumor regression to neoadjuvant
chemoradiotherapy in rectal cancer patients. BMC Med Genomics.
7:682014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Caramés C, Cristóbal I, Moreno V, del
Puerto L, Moreno I, Rodriguez M, Marín JP, Correa AV, Hernández R,
Zenzola V, et al: MicroRNA-21 predicts response to preoperative
chemoradiotherapy in locally advanced rectal cancer. Int J
Colorectal Dis. 30:899–906. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Svoboda M, Izakovicova Holla L, Sefr R,
Vrtkova I, Kocakova I, Tichy B and Dvorak J: Micro-RNAs miR125b and
miR137 are frequently upregulated in response to capecitabine
chemoradiotherapy of rectal cancer. Int J Oncol. 33:541–547.
2008.PubMed/NCBI
|
|
113
|
D'Angelo E, Fassan M, Maretto I,
Pucciarelli S, Zanon C, Digito M, Rugge M, Nitti D and Agostini M:
Serum miR-125b is a non-invasive predictive biomarker of the
pre-operative chemoradiotherapy responsiveness in patients with
rectal adenocarcinoma. Oncotarget. 7:28647–28657. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yu J, Li N, Wang X, Ren H, Wang W, Wang S,
Song Y, Liu Y, Li Y, Zhou X, et al: Circulating serum microRNA-345
correlates with unfavorable pathological response to preoperative
chemo-radiotherapy in locally advanced rectal cancer. Oncotarget.
7:64233–64243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Caramés C, Cristobal I, Moreno V, Marín
JP, González-Alonso P, Torrejón B, Minguez P, Leon A, Martín JI,
Hernández R, et al: MicroRNA-31 emerges as a predictive biomarker
of pathological response and outcome in locally advanced rectal
cancer. Int J Mol Sci. 17:8782016. View Article : Google Scholar :
|
|
116
|
Chiang Y, Song Y, Wang Z, Liu Z, Gao P,
Liang J, Zhu J, Xing C and Xu H: microRNA-192, -194 and -215 are
frequently down-regulated in colorectal cancer. Exp Ther Med.
3:560–566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang B, Shen ZL, Gao ZD, Zhao G, Wang CY,
Yang Y, Zhang JZ, Yan YC, Shen C, Jiang KW, et al: MiR-194,
commonly repressed in colorectal cancer, suppresses tumor growth by
regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle.
14:1046–1058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhao Y, Li F, Zhang X, Liu A, Qi J, Cui H
and Zhao P: MicroRNA-194 acts as a prognostic marker and inhibits
proliferation in hepatocellular carcinoma by targeting MAP4K4. Int
J Clin Exp Pathol. 8:12446–12454. 2015.
|
|
119
|
D'Angelo E, Zanon C, Sensi F, Digito M,
Rugge M, Fassan M, Scarpa M, Pucciarelli S, Nitti D and Agostini M:
miR-194 as predictive biomarker of responsiveness to neoadjuvant
chemoradiotherapy in patients with locally advanced rectal
adenocarcinoma. J Clin Pathol. 71:344–350. 2018. View Article : Google Scholar
|
|
120
|
Slotta-Huspenina J, Drecoll E, Feith M,
Habermehl D, Combs S, Weichert W, Bettstetter M, Becker K and
Langer R: MicroRNA expression profiling for the prediction of
resistance to neoadjuvant radiochemotherapy in squamous cell
carcinoma of the esophagus. J Transl Med. 16:1092018. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Du B, Wang X, Wu D, Wang T, Yang X, Wang
J, Shi X, Chen L and Zhang W: MicroRNA expression profiles identify
biomarkers for predicting the response to chemoradiotherapy in
rectal cancer. Mol Med Rep. 18:1909–1916. 2018.PubMed/NCBI
|
|
122
|
Della Vittoria Scarpati G, Falcetta F,
Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK,
D'Incalci M, De Placido S and Pepe S: A specific miRNA signature
correlates with complete pathological response to neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. Int J Radiat
Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar
|
|
123
|
Hotchi M, Shimada M, Kurita N, Iwata T,
Sato H, Morimoto S, Yoshikawa K, Higashijima J and Miyatani T:
microRNA expression is able to predict response to
chemoradiotherapy in rectal cancer. Mol Clin Oncol. 1:137–142.
2013.PubMed/NCBI
|
|
124
|
Kheirelseid EA, Miller N, Chang KH, Curran
C, Hennessey E, Sheehan M, Newell J, Lemetre C, Balls G and Kerin
MJ: miRNA expressions in rectal cancer as predictors of response to
neoadjuvant chemoradiation therapy. Int J Colorectal Dis.
28:247–260. 2013. View Article : Google Scholar
|
|
125
|
Svoboda M, Sana J, Fabian P, Kocakova I,
Gombosova J, Nekvindova J, Radova L, Vyzula R and Slaby O: MicroRNA
expression profile associated with response to neoadjuvant
chemoradiotherapy in locally advanced rectal cancer patients.
Radiat Oncol. 7:1952012. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Calanzani N, Druce PE, Snudden C, Milley
KM, Boscott R, Behiyat D, Saji S, Martinez-Gutierrez J, Oberoi J,
Funston G, et al: Identifying novel biomarkers ready for evaluation
in low-prevalence populations for the early detection of upper
gastrointestinal cancers: A systematic review. Adv Ther. Dec
11–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Azizian A, Epping I, Kramer F, Jo P,
Bernhardt M, Kitz J, Salinas G, Wolff HA, Grade M, Beißbarth T, et
al: Prognostic value of MicroRNAs in preoperative treated rectal
cancer. Int J Mol Sci. 17:5682016. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-cell translocation gene 4 is associated with
CpG island methylation in colorectal cancer. Cancer Res.
68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Campayo M, Navarro A, Benítez JC,
Santasusagna S, Ferrer C, Monzó M and Cirera L: miR-21, miR-99b and
miR-375 combination as predictive response signature for
preoperative chemoradiotherapy in rectal cancer. PLoS One.
13:e02065422018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Machackova T, Trachtova K, Prochazka V,
Grolich T, Farkasova M, Fiala L, Sefr R, Kiss I, Skrovina M,
Dosoudil M, et al: Tumor microRNAs identified by small RNA
sequencing as potential response predictors in locally advanced
rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Cancer Genomics Proteomics. 17:249–257. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Li AL, Chung TS, Chan YN, Chen CL, Lin SC,
Chiang YR, Lin CH, Chen CC and Ma N: microRNA expression pattern as
an ancillary prognostic signature for radiotherapy. J Transl Med.
16:3412018. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Renganathan A and Felley-Bosco E: Long
noncoding RNAs in cancer and therapeutic potential. Adv Exp Med
Biol. 1008:199–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Guzel E, Okyay TM, Yalcinkaya B,
Karacaoglu S, Gocmen M and Akcakuyu MH: Tumor suppressor and
oncogenic role of long non-coding RNAs in cancer. North Clin
Istanb. 7:81–86. 2019.
|
|
135
|
Zhang H, Chen Z, Wang X, Huang Z, He Z and
Chen Y: Long non-coding RNA: A new player in cancer. J Hematol
Oncol. 6:372013. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Rasool M, Malik A, Zahid S, Basit Ashraf
MA, Qazi MH, Asif M, Zaheer A, Arshad M, Raza A and Jamal MS:
Non-coding RNAs in cancer diagnosis and therapy. Noncoding RNA Res.
1:69–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Dizaji BF: Strategies to target long
non-coding RNAs in cancer treatment: Progress and challenges. Egypt
J Med Hum Genet. 21:412020. View Article : Google Scholar
|
|
138
|
Yang N: An overview of viral and nonviral
delivery systems for microRNA. Int J Pharm Investig. 5:179–181.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Labatut AE and Mattheolabakis G: Non-viral
based miR delivery and recent developments. Eur J Pharm Biopharm.
128:82–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Zhang Y, Wang Z and Gemeinhart RA:
Progress in microRNA delivery. J Control Release. 172:962–974.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Meng WJ, Yan H, Zhou B, Zhang W, Kong XH,
Wang R, Zhan L, Li Y, Zhou ZG and Sun XF: Correlation of SATB1
overexpression with the progression of human rectal cancer. Int J
Colorectal Dis. 27:143–150. 2012. View Article : Google Scholar
|
|
142
|
Zhang P, Wang L, Rodriguez-Aguayo C, Yuan
Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, et al: miR-205
acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat
Commun. 5:56712014. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Huang X, Taeb S, Jahangiri S, Emmenegger
U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, et al:
miRNA-95 mediates radioresistance in tumors by targeting the
sphingolipid phosphatase SGPP1. Cancer Res. 73:6972–6986. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Ha Thi HT, Kim HY, Kim YM and Hong S:
MicroRNA-130a modulates a radiosensitivity of rectal cancer by
targeting SOX4. Neoplasia. 21:882–892. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Kelley KA, Ruhl RA, Rana SR, Dewey E,
Espinosa C, Thomas CR Jr, Martindale RG, Anand S and Tsikitis VL:
Understanding and resetting radiation sensitivity in rectal cancer.
Ann Surg. 266:610–616. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Ruhl R, Rana S, Kelley K, Espinosa-Diez C,
Hudson C, Lanciault C, Thomas CR Jr, Liana Tsikitis V and Anand S:
microRNA-451a regulates colorectal cancer proliferation in response
to radiation. BMC Cancer. 18:5172018. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Luo J, Liu L, Zhou N, Shen J, Sun Q, Zhu Y
and Chen M: miR-519b-3p promotes responsiveness to preoperative
chemo-radiotherapy in rectal cancer patients by targeting ARID4B.
Gene. 655:84–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Winter SF, Lukes L, Walker RC, Welch DR
and Hunter KW: Allelic variation and differential expression of the
mSIN3A histone deacetylase complex gene Arid4b promote mammary
tumor growth and metastasis. PLoS Genet. 8:e10027352012. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yang P, Yang Y, An W, Xu J, Zhang G, Jie J
and Zhang Q: The long noncoding RNA-ROR promotes the resistance of
radiotherapy for human colorectal cancer cells by targeting the
p53/miR-145 pathway. J Gastroenterol Hepatol. 32:837–845. 2017.
View Article : Google Scholar
|
|
150
|
Zou Y, Yao S, Chen X, Liu D, Wang J, Yuan
X, Rao J, Xiong H, Yu S, Yuan X, et al: LncRNA OIP5-AS1 regulates
radioresistance by targeting DYRK1A through miR-369-3p in
colorectal cancer cells. Eur J Cell Biol. 97:369–378. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Wang G, Li Z, Zhao Q, Zhu Y, Zhao C, Li X,
Ma Z, Li X and Zhang Y: LincRNA-p21 enhances the sensitivity of
radiotherapy for human colorectal cancer by targeting the
Wnt/β-catenin signaling pathway. Oncol Rep. 31:1839–1845. 2014.
View Article : Google Scholar : PubMed/NCBI
|
